|
|
|
|||
|
| ||||
| ||||
| ||||
|
|
|
Ernst & Young says Indian pharmaceutical industry holds a competitive advantage
India’s Pharmaceutical sector is on the move. It is holding a solid competitive advantage according a leading think tanks and global consulting firm.
Global consultants Ernst & Young today said the Indian pharmaceutical industry would hold a competitive advantage in the new product patent regime and no global pharmaceutical supply chain can ignore its relevance.
"India is becoming an integral part of the pharma value chain, as large global pharma companies continue to increase their sourcing of APIs, offshoring of clinical development and partnering with domestic companies for new product development and marketing, in India," according to `Progressions 2005'', E&Y's third annual report on global trends in the pharma sector.
Beyond the country's impact on innovation and manufacturing of the pharma sector, India will have a larger impact on global pharma's tax, regulatory and IT environment, it said.
E&Y said that collaborations will provide an opportunity to the Indian companies to tap into the world's global research networks and to gain access to new technologies while providing a platform for big global pharma companies to leverage the scientific talent available in India.
Creation of a business and regulatory environment conducive for innovation and research will lead to significant investments in the country, it said.
OUTSOURCING ARTICLES
|
|
| Click here to get ad specs and place your ad or Click here to contact the advertisement department |
Send Letters to the Editor |